Briacell Therap (NASDAQ:BCTX) Sees Large Decline in Short Interest

Briacell Therap (NASDAQ:BCTX) saw a large decline in short interest in the month of December. As of December 15th, there was short interest totaling 102,341 shares, a decline of 17.1% from the November 30th total of 123,407 shares. Currently, 5.8% of the shares of the company are short sold. Based on an average daily trading volume, of 62,408 shares, the days-to-cover ratio is presently 1.6 days. Based on an average daily trading volume, of 62,408 shares, the days-to-cover ratio is presently 1.6 days. Currently, 5.8% of the shares of the company are short sold.

Institutional Investors Weigh In On Briacell Therap

An institutional investor recently bought a new position in Briacell Therap stock. Citadel Advisors LLC purchased a new position in shares of Briacell Therap (NASDAQ:BCTX) during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund purchased 11,055 shares of the company’s stock, valued at approximately $122,000. Citadel Advisors LLC owned approximately 1.63% of Briacell Therap at the end of the most recent reporting period. 15.42% of the stock is currently owned by hedge funds and other institutional investors.

Briacell Therap Stock Performance

Briacell Therap stock opened at $7.11 on Friday. Briacell Therap has a one year low of $6.00 and a one year high of $98.20. The business has a fifty day moving average of $9.81 and a two-hundred day moving average of $12.14. The company has a market cap of $13.37 million, a P/E ratio of -0.16 and a beta of 1.38.

Briacell Therap (NASDAQ:BCTX) last announced its quarterly earnings results on Monday, December 15th. The company reported ($4.35) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($12.11) by $7.76. Sell-side analysts predict that Briacell Therap will post -2.45 EPS for the current year.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Briacell Therap in a report on Wednesday, October 8th. One research analyst has rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock currently has an average rating of “Hold” and an average price target of $320.00.

Briacell Therap Company Profile

BriaCell Therapeutics Corp., a clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted cell-based immunotherapy that is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer. The company is also developing Bria-OTS, a platform of personalized off-the-shelf cell-based immunotherapies, which is being evaluated in a Phase 1/2 clinical studies targeting breast cancer with extension to prostate cancer and other cancers.